Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | TGM2 | P21980 | 2/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518555 | 0.88 | CES1 (0.46) | IDO1TGM2TDO2CES1LMNA | |
| SCHEMBL9210797 | 0.78 | MAPT (0.45) | IDO1TGM2LMNAMEN1KMT2A | |
| SCHEMBL9210259 | 0.74 | CES1 (0.47) | CES1TP53MDM2 | |
| SCHEMBL8303268 | 0.74 | PGR (0.53) | IDO1TGM2TDO2CES1LMNA | |
| SCHEMBL9202056 | 0.72 | CES1 (0.43) | CES1TP53MDM2 | |
| SCHEMBL9000748 | 0.71 | CES1 (0.44) | CES1TP53MDM2 | |
| SCHEMBL9201592 | 0.70 | TDP2 (0.50) | CES1LMNAMEN1KMT2A | |
| SCHEMBL9200031 | 0.70 | CES1 (0.43) | CES1LMNAPGRTP53MDM2 | |
| SCHEMBL9207175 | 0.70 | CES1 (0.43) | CES1TP53MDM2 | |
| SCHEMBL7485845 | 0.69 | TGM2 (0.53) | IDO1TGM2TDO2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | IDO1 4419/4885TGM2 1887/4885TDO2 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.